Human immunodeficiency virus 1 envelope glycoprotein gp120 V3 loop T-cell epitope (HIV-1 gp120 V3 epitope)

HLA-presented T-cell epitopes derived from the HIV-1 gp120 V3 loop are short peptide fragments of the viral envelope protein displayed on the surface of infected cells by Human Leukocyte Antigen (HLA) molecules (UniProt: P04578). The V3 loop is a critical region of the gp120 protein, primarily responsible for determining viral co-receptor usage (CCR5 or CXCR4) and serving as a major target for the host immune system (PubMed: 11752708). When these epitopes are recognized by T-cell receptors (TCRs) on CD8+ cytotoxic T lymphocytes or CD4+ helper T cells, they trigger an adaptive immune response aimed at eliminating HIV-infected cells (NIH: HIV Vaccine Research). Because the V3 loop is highly variable, these epitopes are central to research in developing vaccines that can overcome viral diversity, such as those tested in the RV144 clinical trial (PubMed: 22992294). Therapeutic strategies targeting these epitopes include peptide-based vaccines, viral vector vaccines, and TCR-engineered T-cell therapies designed to enhance the breadth and potency of the cellular immune response against HIV-1.

Other names

HIV-1 gp120 V3 loop peptideMHC-restricted HIV-1 V3 epitopegp120 V3-derived HLA ligandHIV-1 V3 loop antigenV3 loop T-cell epitope

Induction of antigen-specific cellular immune responses through T-cell receptor recognition of HLA-peptide complexes, leading to the destruction of infected cells.